

Features related to respiratory disability and performance of inhaler technique in COPD population.

Sérgio Marques¹, Zilda Mendes², Sónia Romano², Vera Afreixo^{1,3}, António T. Rodrigues^{4,5}

¹Department of Mathematics, University of Aveiro, Portugal

²Centre for Health Evaluation & Research/Infosaúde – National Association of Pharmacies (CEFAR/IS-ANF), Lisbon, Portugal

³Center for Research and Development in Mathematics and Applications (CIDMA), University of Aveiro, Portugal

⁴Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal

⁵ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal

Introduction:

Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases treated in the community setting [1]. If not appropriately managed can result in poorer health, negative societal and economic effects, with a significant burden on patients' quality of life [1].

COPD cannot be cured, but treatment can help slow down disease progression and control of the symptoms. Treatments may include non-pharmacological approaches as smoking cessation, or pharmacological inhaled therapy, pulmonary rehabilitation, and in very few cases surgery or lung transplant [2], depending on medical doctor assessment of each individual case to provide tailored therapy.

This work aimed to explore which features of patients with COPD can be related with respiratory disability and the performance of inhaler technique in Portugal.

Methods:

Data for this work were obtained from the Pilot Project INspira – Study of inhaler use in asthma and COPD (January to November 2019) patients. A cluster randomized controlled trial, was conducted in the community pharmacies affiliated to National Association of Pharmacies to improve inhalation technique among COPD patients with inhaled therapy [3, 4]. Eligible patients were adults aged 18 years or older using at least 1 of the targeted inhalers (both chronic or first user), and a self-reported diagnosis of COPD. The self-reported diagnosis was checked by the pharmacist, using a differential algorithm [4].

Data on sociodemographic features (i.e., sex, age, educational level, occupational status, tobacco exposure), body mass index (BMI), number of comorbidities, number of different medicines and inhalators used by patients to control the disease, respiratory disability, and performance of inhaler technique, were collected prior to any education have been provided. Respiratory disability was quantified according to the modified Medical Research Council dyspnea (mMRC) scale [5, 6]. This tool comprises five statements describing the entire range of respiratory disability from none (score 0) to almost complete incapacity (score 4). Values of mMRC ≥ 2 were classified as more symptomatic. Inhaler technique was considered well performed when all steps (100%) of the inhalation process were executed correctly, and not well performed if patient failed at least one step.

For purposes of descriptive statistics, continuous variables were summarized by median and interquartile range and categorical variables by counts and percentages. Quantitative variables were analysed through the Mann-Whitney Wilcoxon Test and qualitative ones through Fisher's exact test.

Univariate logistic regression was used to select all candidate variables ($p \leq 0.25$) to enter in multivariate logistic regression. Multimodel inference was performed and the models with lowest AIC were proposed as final models. Odds ratios (OR) and 95% confidence intervals (CI) were calculated.

Results were considered statistically significant at $p < 0.05$.

Results and conclusions:

A sample of 84 patients with available mMRC scores and inhaler technique scores was analysed. Patients' main features are summarised in Table 1. The number of medicines taken to control the disease and the educational level, were significantly associated with the respiratory disability and the performance of inhaler technique, respectively.

From the univariate logistic regressions (Table 2), BMI, number of medicines and number of comorbidities were selected to integrate the respiratory disability multivariate logistic regression. Sex, tobacco exposure and educational level were selected to integrate the performance of the inhaler technique multivariate logistic regression.

Keywords:

Chronic disease, COPD, Dyspnea, Inhaler technique, Modeling, Respiratory disability

Corresponding author:

Sérgio Marques
spedrosa.marques@ua.pt

Support statement:

Pilot Project INspira – Study of inhaler use in asthma and COPD was funded by the Portuguese National Association of Pharmacies. The funder had no role in the design of the study; management, analysis, and interpretation of the data; preparation; review, or approval of the manuscript; and decision to submit the manuscript for publication. Vera Afreixo was supported by FCT through CIDMA and projects UIDB/04106/2020 and UIDP/04106/2020.


Conflict of interest:

The authors declare the following financial interests/ personal relationships which may be considered as potential competing interests: ZM, SR and ATR are/were employees of Infosaúde, a company owned by Portuguese National Association of Pharmacies. SM and VA declare no conflict of interests.

Clinical study registration

number: ISRCTN10844309
<https://doi.org/10.1186/ISRCTN10844309>

First published: 20JUL2022



© 2022 The Authors. This is an open access article distributed under CC BY license, which license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use (<https://creativecommons.org/licenses/by/4.0/>).



Table 1 – Descriptive Statistics of the chronic obstructive pulmonary disease (COPD) sample by respiratory disability and by performance of inhaler technique.

| Variable | Respiratory disability | | | Performance of inhaler technique | | |
|--------------------------------|------------------------|---------------------|---------|--------------------------------------|----------------------------------|----------------|
| | More symptomatic | Less symptomatic | p-value | Not well performed inhaler technique | Well performed inhaler technique | p-value |
| | N (%) | N (%) | | N (%) | N (%) | |
| Sex | | | | | | |
| Male | 18 (40) | 27 (60) | 0.384 | 32 (84) | 6 (16) | 0.050 |
| Female | 19 (50) | 19 (50) | | 18 (62) | 11 (38) | |
| Age | | | | | | |
| <65 years old | 12 (44) | 15 (56) | 1.000 | 16 (70) | 7 (30) | 0.560 |
| ≥ 65 years old | 25 (45) | 31 (55) | | 34 (77) | 10 (23) | |
| Educational level | | | | | | |
| Primary | 14 (47) | 16 (53) | 0.878 | 20 (91) | 2 (9) | 0.007** |
| Sixth or ninth grades | 8 (50) | 8 (50) | | 14 (88) | 2 (13) | |
| Secondary or university | 15 (42) | 21 (58) | | 16 (55) | 13 (45) | |
| Occupational status | | | | | | |
| Employed | 5 (36) | 9 (64) | 0.562 | 8 (73) | 3 (27) | 1.000 |
| Retired or Unemployed | 32 (46) | 37 (54) | | 42 (75) | 14 (25) | |
| Tobacco exposure | | | | | | |
| Never smoked | 8 (53) | 7 (47) | 0.790 | 7 (58) | 5 (42) | 0.377 |
| Ex-smoker | 20 (43) | 27 (57) | | 29 (76) | 9 (24) | |
| Active smoker | 9 (43) | 12 (57) | | 14 (82) | 3 (18) | |
| Respiratory disability | | | | | | |
| More symptomatic | - | - | - | 22 (71) | 9 (29) | 0.587 |
| Less symptomatic | - | - | - | 27 (77) | 8 (23) | |
| Inhaler technique | | | | | | |
| Not well performed | 22 (45) | 27 (55) | 0.587 | - | - | - |
| Well performed | 9 (53) | 8 (47) | | - | - | |
| | Median (IQR) | Median (IQR) | | Median (IQR) | Median (IQR) | |
| Body mass index (BMI) | 27.68 (6.07) | 26.18 (5.42) | 0.140 | 27.65 (6.52) | 26.64 (5.43) | 0.757 |
| Number of inhalators | 1.00 (0.00) | 1.00 (0.00) | 0.565 | 1.00 (0.00) | 1.00 (0.00) | 0.599 |
| Number of medicines | 2.00 (2.00) | 1.00 (1.00) | 0.018* | 1.00 (1.00) | 1.00 (1.00) | 0.550 |
| Number of comorbidities | 2.00 (3.00) | 2.00 (2.00) | 0.088 | 2.00 (2.00) | 2.00 (1.00) | 0.813 |

IQR – Interquartile Range; * p-value < 0.05; **p-value < 0.01.

Table 2 – Univariate Logistic regression results for respiratory disability and performance of inhaler technique outcomes.

| Variable | Respiratory disability | | | Performance of inhaler technique | | |
|---|------------------------|-----------|---------------|----------------------------------|------------|---------------|
| | OR | CI | p-value | OR | CI | p-value |
| Sex (Male) | 1.50 | 0.63-3.62 | 0.362 | 0.31 | 0.09-0.94 | 0.044* |
| Age (>=65) | 0.99 | 0.39-2.50 | 0.986 | 0.67 | 0.22-2.15 | 0.493 |
| Body mass index (BMI) | 0.90 | 0.81-0.99 | 0.038* | 0.99 | 0.89-1.09 | 0.807 |
| Number of inhalers | 0.71 | 0.25-1.87 | 0.493 | 0.83 | 0.21-2.40 | 0.759 |
| Number of medicines | 0.63 | 0.40-0.94 | 0.031* | 0.90 | 0.53-1.41 | 0.650 |
| Number of comorbidities | 0.73 | 0.52-0.98 | 0.046* | 0.93 | 0.62-1.36 | 0.726 |
| Respiratory disability | - | - | - | 0.72 | 0.23-2.20 | 0.568 |
| Performance of inhaler technique | 0.72 | 0.23-2.20 | 0.568 | - | - | - |
| Tobacco exposure (Active Smoker) | 0.99 | 0.35-2.85 | 0.981 | 0.69 | 0.14-2.74 | 0.618 |
| Tobacco exposure (Never smoked) | 0.65 | 0.20-2.09 | 0.467 | 2.30 | 0.56-9.15 | 0.233* |
| Occupational status (Retired or Unemployed) | 0.64 | 0.18-2.06 | 0.467 | 0.89 | 0.22-4.48 | 0.874 |
| Educational level (Sixth or ninth grades) | 0.88 | 0.26-2.98 | 0.829 | 1.43 | 0.16-13.10 | 0.736 |
| Educational level (Secondary or University) | 1.23 | 0.46-3.28 | 0.684 | 8.13 | 1.89-57.00 | 0.012* |

OR – Odds Ratio; CI – confidence interval; * p-value ≤ 0.25

Due to the existence of incomplete cases in the initial data set, the multivariate logistic regression analysis was performed with 66 COPD patients. In the respiratory disability multivariate model, only the number of medicines showed to be significant (p = 0.044), when adjusted to BMI. As the number of medicines used increases, the respiratory disability increases. In the performance of the inhaler technique multivariate model, only the educational level showed to be significant (p = 0.005), when adjusted to tobacco exposure. Patients with a secondary or university degree were 14 times more likely to perform the inhalation technique correctly than individuals with primary school (Table 3).

The positive association between the number of medicines used by patients and the respiratory disability is an interesting result, since the prescription of a greater number of medicines by the doctors will have

Table 3 – Multivariate logistic final models of respiratory disability and performance of the inhaler technique in people with chronic obstructive pulmonary disease (COPD).

| | Coefficients Estimate | SE | OR | 95% CI | p-value |
|---|-----------------------|------|-------|-------------|----------------|
| Respiratory disability | | | | | |
| (Intercept) | 3.33 | 1.56 | 28.01 | 1.62-785.42 | 0.032* |
| Body mass index (BMI) | -0.09 | 0.05 | 0.92 | 0.82-1.01 | 0.094 |
| Number of medicines | -0.49 | 0.24 | 0.61 | 0.37-0.96 | 0.044* |
| Performance of Inhaler technique | | | | | |
| (Intercept) | -2.79 | 0.89 | 0.06 | 0.00-0.26 | 0.002** |
| Tobacco exposure (Active Smoker) | -0.85 | 0.82 | 0.43 | 0.08-1.99 | 0.300 |
| Tobacco exposure (Never smoked) | 1.72 | 0.95 | 5.60 | 0.96-46.82 | 0.070 |
| Educational level (Sixth or ninth grades) | 0.19 | 1.14 | 1.20 | 0.11-12.33 | 0.870 |
| Educational level (Secondary or University) | 2.71 | 0.95 | 14.97 | 2.86-140.00 | 0.005** |

* p-value < 0.05; ** p-value < 0.01

the objective of greater effectiveness in controlling the disease or reduce its severity. However, it is known that polypharmacy tends to increase poor medication adherence [7, 8], and thus reducing the effectiveness of the medication, and consequently worsening disease.

On the other hand, as expected, according to previous literature [9–13], our results show that educational level is significantly associated to the performance of the inhaler technique. The correct inhaled technique favors therapeutic effectiveness and consequently better outcomes, namely better symptom control, lower risk of exacerbations, and improved quality of life [14, 15].

Ethics committee and informed consent:

The current research was approved by an independent ethics committee and patients gave their informed consent before they were enrolled in the study. Ethics compliant 10/12/2018, Ethics Committee Institute of Bioethics of Universidade Católica Portuguesa (Instituto de Bioética, Universidade Católica Portuguesa, Porto, Rua de Diogo Botelho, 1327, 4169-005 Porto, Portugal).

Clinical study registration number: ISRCTN10844309 <https://doi.org/10.1186/ISRCTN10844309>

Acknowledgements:

The authors are grateful to all community pharmacies who participated in the study and all participants who voluntarily agreed to complete the survey.

References:

1. Observatório Nacional das Doenças Respiratórias. 11.º Relatório – Prevenir as Doenças Respiratórias, Acompanhar e Reabilitar os Doentes; 2016.
2. Morris, SY. What Are the First-Line Treatments for COPD? Healthline. 2017. Available from <https://www.healthline.com/health/copd/first-line-treatments>.
3. Teixeira A. Inspira Estudo Piloto. Webinar XI Congresso da Fundação Portuguesa do Pulmão. 29 e 30 de 2020.
4. Rodrigues AT, Romano S, Romão M, et al. Effectiveness of a pharmacist-led intervention on inhalation technique for asthma and COPD patients: The INSPIRA pilot cluster-randomized controlled trial. *Respir. Med.* 2021 Aug-Sep;185:106507. <https://doi.org/10.1016/j.rmed.2021.106507>
5. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax.* 1999;54(7):581–586. <https://doi.org/10.1136/thx.54.7.581>
6. Kovelis D, Segretti NO, Probst VS, et al. Validação do Modified Pulmonary Functional Status and Dyspnea Questionnaire e da escala do Medical Research Council para o uso em pacientes com doença pulmonar obstrutiva crônica no Brasil. *J. Bras. Pneumol.* 2008;34(12):1008–1018. <https://doi.org/10.1590/S1806-37132008001200005>
7. Vetrano DL, Bianchini E, Onder G, et al. Poor adherence to chronic obstructive pulmonary disease medications in primary care: Role of age, disease burden and polypharmacy. *Geriatr Gerontol Int.* 2017 Dec;17(12):2500–2506. <https://doi.org/10.1111/ggi.13115>
8. Moradkhani B, Mollazadeh S, Niloofar P, et al. Association between medication adherence and health-related quality of life in patients with chronic obstructive pulmonary disease. *J Pharm Health Care Sci.* 2021 Nov;15;7(1):40. <https://doi.org/10.1186/s40780-021-00222-x>
9. Maricoto TJP. Inhaler technique performance in elderly patients with asthma and COPD. PhD thesis in Medicine. University Of Beira Interior. Covilhã, October 2019.
10. Maricoto T, Rodrigues LV, Teixeira G, et al. Assessment of Inhalation Technique in Clinical and Functional Control of Asthma and Chronic Obstructive Pulmonary Disease. *Acta Med Port.* 2015 Nov-Dec;28(6):702–7. <https://doi.org/10.20344/amp.5905>
11. Beatty CR, Flynn LA, Costello TJ. The Impact of Health Literacy Level on Inhaler Technique in Patients with Chronic Obstructive Pulmonary Disease. *J Pharm Pract.* 2017 Feb;30(1):25–30. <https://doi.org/10.1177/0897190015585759>
12. Dalcin Pde T, Grutcki DM, Laporte PP, et al. Factors related to the incorrect use of inhalers by asthma patients. *J Bras Pneumol.* 2014;40(1):13–20. <https://doi.org/10.1590/S1806-37132014000100003>
13. Aydemir Y. Assessment of the factors affecting the failure to use inhaler devices before and after training. *Respir Med.* 2015;109(4):451–8. <https://doi.org/10.1016/j.rmed.2015.02.011>
14. Giraud V, Allaert FA, Roche N. Inhaler technique and asthma: feasibility and acceptability of training by pharmacists. *Respir Med.* 2011;105:1815–22. <https://doi.org/10.1016/j.rmed.2011.07.004>
15. Rabe KF, Schmidt DT. Pharmacological treatment of asthma today. *European Respiratory Journal* 2001 34: 34s–40s. <https://doi.org/10.1183/09031936.01.00252501>